Therefore, we conclude that the development of targeted molecules to inhibit CXCL1 and CXCL8 may be a promising strategy for suppressing ovarian cancer progression and achieving therapeutic benefits. The gene discussed is CXCL1; the disease is ovarian carcinoma.